4 March 2024

ValiRx PLC ("ValiRx" or the "Company")

Proposed Appointment of Non-Executive Director

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health is pleased to announce that, subject to normal regulatory due diligence, it intends to appoint Luke Cairns as an Independent Non-Executive Director of the Company.

Luke is an experienced corporate finance professional with over 20 years of working with SMEs as both an adviser and director. He was previously Head of Corporate Finance and Joint Managing Director at Northland Capital Partners Limited, an AIM Nominated Adviser and broker firm, and has worked with many companies across several sectors and regions on a wide range of transactions, including IPOs, secondary fundraisings, corporate restructurings and takeovers.

Subsequently, Luke set up his own consultancy working with growth companies and family offices and now sits on number of private and public boards.

Dr Kevin Cox, Chair of ValiRx PLC, commented "Luke will be an excellent addition to the Board of ValiRx given his extensive experience in small companies, corporate finance and corporate governance. He will provide help and advice across all areas of the business but particularly in respect of ValiRx as a quoted company. His independent and objective views will help ensure continued progress of our strategic plans." 

Dr Suzy Dilly, CEO of ValiRx PLC commented "I'm looking forward to working with Luke, drawing on his public market experience and in doing so enabling me to focus on driving the business forward in line with all our shareholders ambitions."

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.

For more information, please contact:

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

Cautionary statement

Certain statements made in this announcement are forward-looking statements. Such statements are based on current expectations and assumptions and are subject to a number of risks and uncertainties that could cause actual events or results to differ materially from any expected future events or results expressed or implied in these forward-looking statements. Persons receiving this announcement should not place undue reliance on forward-looking statements. Unless otherwise required by applicable law, regulation or accounting standard, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.